688298 Stock Overview
Researches and develops, produces, and sells in vitro diagnostic products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Zhejiang Orient Gene Biotech Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥30.70 |
| 52 Week High | CN¥41.49 |
| 52 Week Low | CN¥24.40 |
| Beta | 1.7 |
| 1 Month Change | -7.42% |
| 3 Month Change | 11.31% |
| 1 Year Change | -11.68% |
| 3 Year Change | -74.68% |
| 5 Year Change | n/a |
| Change since IPO | -64.67% |
Recent News & Updates
Subdued Growth No Barrier To Zhejiang Orient Gene Biotech Co., Ltd's (SHSE:688298) Price
Dec 17
Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Weighed On By Its Debt Load?
Aug 20Shareholder Returns
| 688298 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 1.7% | -3.0% | -2.1% |
| 1Y | -11.7% | -19.0% | 9.8% |
Return vs Industry: 688298 exceeded the CN Biotechs industry which returned -19% over the past year.
Return vs Market: 688298 underperformed the CN Market which returned 9.8% over the past year.
Price Volatility
| 688298 volatility | |
|---|---|
| 688298 Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 688298 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688298's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 2,065 | Xiaoliang Fang | www.orientgene.com |
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. The company offers IFA solutions, digital test, oral fluid test, and covid-19 test products; and immunological diagnosis product, such as hair drug test kit, monkeypox, saliva drug test, urine multi-drug test, urine single-drug test, rapid test, digital pregnancy test, male-fertility test, menopause test, and other test products. It also provides molecular diagnosis products, including nucleic acid extraction systems, real time PCR systems, virus detection kits, viral nucleic acid extraction kits, and general products; liquid biochip products; mini immunofluorescence analyzers, handheld fluorescence immunoassay analyzers, fluorescence immunoassay analyzers, handheld oral fluid drug test readers, colloidal gold test readers, and urine drug test cup readers; and dry biochemical strips comprising urine reagent strips, urine analyzers, alcohol test, and vaginal pH test products.
Zhejiang Orient Gene Biotech Co., Ltd Fundamentals Summary
| 688298 fundamental statistics | |
|---|---|
| Market cap | CN¥5.93b |
| Earnings (TTM) | -CN¥587.36m |
| Revenue (TTM) | CN¥825.60m |
7.2x
P/S Ratio-10.1x
P/E RatioIs 688298 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688298 income statement (TTM) | |
|---|---|
| Revenue | CN¥825.60m |
| Cost of Revenue | CN¥660.01m |
| Gross Profit | CN¥165.59m |
| Other Expenses | CN¥752.95m |
| Earnings | -CN¥587.36m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.04 |
| Gross Margin | 20.06% |
| Net Profit Margin | -71.14% |
| Debt/Equity Ratio | 7.2% |
How did 688298 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 17:56 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Orient Gene Biotech Co., Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yiling Chen | Guosen Securities Co., Ltd. |
| Hanqing Zhu | Guosen Securities Co., Ltd. |